Ann: Positive Nine Month RA Results For Mesoblast Cell Therapy, page-35

@madamswer

I am afraid your prediction for MSB cash balance is a little bit too optimistic.

As of 31 December 2016, MSB had US$33.9m.

Early in January, MNK handed over US$21.7m for a 5% stake.

Latest Appendix 4C indicated that cash outgoings in Q3 is expected to be US$26.8m.

Using all of the above figures, we can calculate what MSB's expected cash balance on 31 March 2017 will be.

33.9 + 21.7 - 26.8 = US$28.8m

In other words, in 6 weeks time, without a new partnership deal, MSB will have less money than what it had back on 31 December 2016.

A further 3 months later, if the rate of cash consumption doesn't decrease, its cash will be pretty much gone.

---

All of these announcements about trials results are too difficult for me to understand. Reading it certainly gives me the impression that it's all good news. Because I realise that I don't have the skills to analyse and understand these results, I have no choice but to use announcement of new partnership or lack of announcement to guide me whether or not these results are indeed promising.